Evidence map›Paper›PMID 31324695›Full record

ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2020

Role of endotoxemia in causing renal dysfunction in cirrhosis.

Jennifer L Peng, Witina Techasatian, Takashi Hato, Suthat Liangpunsakul

Open access · greenAbstract readReview
In one paragraph

Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer L Peng *Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Witina Techasatian *Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Takashi HatoDivision of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-6504-8123
Indiana University School of MedicineRichard L. Roudebush VA Medical Center · US

Funding

Novel biomarkers as a clinical tool for excessive alcohol use screeningR01AA025208 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT, TU, WANZHU · 2016 to 2020
$1.7M
Sestrin3 in the pathogenesis of alcoholic and non-alcoholic fatty liver diseaseR01DK107682 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE, LIANGPUNSAKUL, SUTHAT · 2016 to 2019
$1.4M
Immunological Profiles and prognostic outcomes in patients with alcoholic hepatitisU01AA026917 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2022
$1.2M
Novel animal models to study miRNA-mediated alcoholic liver diseaseUH3AA026903 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2020 to 2022
$1.2M
Modulating purine metabolism to treat kidney injury in sepsis.K08DK113223 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI HATO, TAKASHI · 2017 to 2021
$757k
Novel animal models to study miRNA-mediated alcoholic liver diseaseUH2AA026903 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2019
$447k
Serum Proteomic Profiles as Biomarkers of Abusive Alcohol ConsumptionI01CX000361 · VA · RLR VA MEDICAL CENTER · PI LIANGPUNSAKUL, SUTHAT · 2012 to 2025
–
CSRD VA I01 CX000361NIAAA NIH HHS R01 AA025208NIAAA NIH HHS U01 AA026917NIAAA NIH HHS UH2 AA026903NIAAA NIH HHS UH3 AA026903NIDDK NIH HHS K08 DK113223NIDDK NIH HHS R01 DK107682
6 · The paper itself

Abstract

Renal failure is a challenging problem in patients with cirrhosis since mortality increases with worsening renal function, hence the inclusion of serum creatinine in calculating the Model for End-Stage Liver Disease score for liver transplant evaluation. Among the various causes, infection is the leading etiology of mortality associated with cirrhosis. Bacterial infection frequently precipitates renal failure in patients with cirrhosis with the reported prevalence around 34%. Patients with cirrhosis are at increased risk of infections due to impaired immunity and increased gut permeability leading to bacterial translocation in the setting of portal hypertension. One of the most feared complications of severely decompensated liver and renal failure is hepatorenal syndrome, of which liver transplant may be the only available treatment. Furthermore, in those with spontaneous bacterial peritonitis and urinary tract infection, progressive renal failure occurs despite resolution of infection. Thus, the effects of endotoxemia on renal function in cirrhosis have become a major focus of research. The mechanisms of the damaging effects of endotoxin on renal function are complex but, in essence, involve dysregulated inflammation, circulatory dysfunction, poor clearance of endotoxin burden, as well as vasomotor nephropathy. In this article, we will review the mechanisms of endotoxemia-induced renal dysfunction in the setting of cirrhosis through the effects on renal blood flow, renal vascular endothelium, glomerular filtration rate, and tubular function.

Indexed as

EndotoxemiaGlomerular Filtration RateHumansKidneyLiver CirrhosisRenal Insufficiencyacute kidney injurybacterial infectionsliver cirrhosis

Identifiers

PMID31324695
PMCPMC8073210
OpenAlexW2964183146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.